ImmuCell Corporation (ICCC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $97.73M
Last updated: Nov 17, 2026 at 11:06 AM ET
ImmuCell Corporation (ICCC) Competitors
The companies most similar to ImmuCell are Immunic (IMUX), Equillium (EQ) and Coherus BioSciences (CHRS). By market cap, ImmuCell ranks 8th of the 13 companies on this page; Immuneering (IMRX) is the largest at $240.27M.
Peer Comparison
ICCC's ROIC of 4.6% is above the peer median of -126.7%, and its revenue growth of 11.5% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| ImmuCell (ICCC) | $97.73M | 57.2x | 3.1x | 2.6% | 4.6% | 11.5% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Equillium Inc (EQ) | $106.20M | N/A | 29.3x | 0.0% | N/A | -52.3% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| MacroGenics Inc (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| PDS Biotechnology Corp (PDSB) | $107.07M | N/A | N/A | 0.0% | -149.8% | 0.0% | 0.00% |
| Codexis Inc (CDXS) | $127.13M | N/A | N/A | -21.8% | N/A | 124.0% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| INmune Bio Inc (INMB) | $32.51M | N/A | N/A | 0.0% | N/A | 257.1% | 0.00% |
| iBio, Inc. Common Stock (IBIO) | $51.55M | N/A | 735.4x | 0.0% | N/A | 975.0% | 0.00% |
| Immuneering Corp (IMRX) | $240.27M | N/A | N/A | 0.0% | N/A | -99.8% | 0.00% |
| Peer median | $104.40M | N/A | 15.6x | 0.0% | -126.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to ImmuCell, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| Equillium Inc (EQ) | Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory... | EQ competitors |
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| MacroGenics Inc (MGNX) | MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. | MGNX competitors |
| PDS Biotechnology Corp (PDSB) | PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. | PDSB competitors |
| Codexis Inc (CDXS) | Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California. | CDXS competitors |
| ImageneBio, Inc. (IMA) | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
| Anixa Biosciences Inc (ANIX) | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
| INmune Bio Inc (INMB) | INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease... | INMB competitors |
| iBio, Inc. Common Stock (IBIO) | iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States. | IBIO competitors |
| Immuneering Corp (IMRX) | Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its... | IMRX competitors |
Frequently Asked Questions About ICCC
Who are ImmuCell's main competitors?
The companies most similar to ImmuCell include Immunic (IMUX), Equillium (EQ), Coherus BioSciences (CHRS), MacroGenics (MGNX) and PDS Biotechnology (PDSB), listed from the closest match.
Who is ImmuCell's biggest competitor?
Immuneering (IMRX) is the largest of the similar companies at $240.27M; Immunic (IMUX) is the closest match by business profile, size, sector and industry.
How does ICCC stock compare with its competitors?
ICCC's P/S is 3.1x against a peer median of 15.6x; its net margin is 2.6% against a peer median of 0.0%.
Which of ImmuCell's competitors pays a higher dividend?
ImmuCell pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is ImmuCell bigger than its competitors?
No. ImmuCell is 8th by market cap among the 13 companies on this page; the largest is Immuneering (IMRX) at $240.27M.
ICCC pages: Overview, Earnings, Financials, Valuation, Competitors